Articles

Approving cancer treatments based on endpoints other than overall survival: an analysis of historical data using the PACE Continuous Innovation Indicators™ (CII)

Neon Brooks, Mario Campone, Silvia Paddock, Scott Shortenhaus, David Grainger, Jacqueline Zummo, Samuel Thomas, Rose Li

Article Type

Original Research

Published

This article examines the relationship between U.S. Food and Drug Administration (FDA) approval and the publication of OS evidence to understand better the risks and benefits of delaying approval until OS evidence is available.

Read more

Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies

Sabrina Rossi, Alessandra Cassano, Antonia Strippoli, Giovanni Schinzari, Ettore D’Argento, Michele Basso, Carlo Barone

Article Type

Original Research

Published

This retrospective study looks to find specific predictive criteria related to patient or tumor characteristics in order to select patients that might benefit the most from eribulin and define the correct treatment sequence.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.